Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Let's kick off the next session. It is my pleasure to welcome Protagonist Therapeutics. And with me today is Dinesh Patel, CEO of the company. We have a lot to go through. There's a lot of excitement with the product launches and the pipeline that we're going to hopefully learn more later this year. Before we get to them, I'm going to turn it to you for opening remarks.
Yes. Well, first and foremost, thanks for inviting us. That is something we truly appreciate. And hopefully, they will continue.
But I think Protagonist is at an unusually interesting and positive space right now. If you think about it, we are now a commercial company through our drug ICOTYDE, partnered with J&J. We could be looking forward to potential approval of rusfertide in the third quarter. That's when the PDUFA date is in August. And the Phase III data has been outstanding.
So that is partnered with Takeda. And if that gets approved, then I guess we'll be a biotech with 2 approved drugs this year. That's nice statistics.
And then the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
